News
Venture Kick Stage III – Winner
GlioCART has obtained CHF 150,000 from Venture Kick to develop a new type of cell therapy – the first CAR-T cell therapy – designed to target both glioblastoma tumors and the surrounding immunesuppressive environment.
Venture Leader Biotech Roadshow –
Participant
GlioCART has been selected as one of ten Swiss biotech startups for the Venture Leaders Biotech 2026 roadshow in Boston.
The program offers a unique opportunity to connect with investors, industry experts, and partners in one of the world’s leading biotech hubs.
